Search

Author/Creator Naso, Giuseppe

1. Bevacizumab as First-Line Treatment in HER2-Negative Advanced Breast Cancer: Pros and Cons. Issue 5 (September 2016)

Authors:
Sini, Valentina; Cassano, Alessandra; Corsi, Domenico; De Laurentiis, Michele; Gamucci, Teresa; Mauri, Mariella; Naso, Giuseppe; Roselli, Mario; Maria Ruggeri, Enzo; Tonini, Giuseppe; Vici, Patrizia; Zampa, Germano; Marchetti, Paolo
Journal:
Tumori
Issue:
Volume 102:Issue 5(2016)
Page Start:
472
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. (July 2021)

Authors:
Gelmon, Karen A.; Fasching, Peter A.; Couch, Fergus J.; Balmaña, Judith; Delaloge, Suzette; Labidi-Galy, Intidhar; Bennett, James; McCutcheon, Susan; Walker, Graham; O'Shaughnessy, Joyce; Timcheva, Constanta; Tomova, Antoaneta; Eisen, Andrea; Gelmon, Karen; Lemieux, Julie; Bazan, Fernando; Bourge...
Journal:
European journal of cancer
Issue:
Volume 152(2021)
Page Start:
68
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?. (14th December 2017)

Authors:
Cerbelli, Bruna; Pernazza, Angelina; Botticelli, Andrea; Fortunato, Lucio; Monti, Massimo; Sciattella, Paolo; Campagna, Domenico; Mazzuca, Federica; Mauri, Maria; Naso, Giuseppe; Marchetti, Paolo; d'Amati, Giulia; Costarelli, Leopoldo
Other Names:
Gasparri Maria L. Academic Editor.
Journal:
BioMed research international
Issue:
Volume 2017(2017)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗